DK0665013T3 - Behandling af hyperproliferative karsygdomme - Google Patents

Behandling af hyperproliferative karsygdomme

Info

Publication number
DK0665013T3
DK0665013T3 DK95100194T DK95100194T DK0665013T3 DK 0665013 T3 DK0665013 T3 DK 0665013T3 DK 95100194 T DK95100194 T DK 95100194T DK 95100194 T DK95100194 T DK 95100194T DK 0665013 T3 DK0665013 T3 DK 0665013T3
Authority
DK
Denmark
Prior art keywords
vascular disease
treatment
hyperproliferative vascular
mammal
hyperproliferative
Prior art date
Application number
DK95100194T
Other languages
Danish (da)
English (en)
Inventor
Robert Ryder Dr Bartlett
Randall E Morris
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0665013T3 publication Critical patent/DK0665013T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK95100194T 1994-01-13 1995-01-09 Behandling af hyperproliferative karsygdomme DK0665013T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/181,116 US5519042A (en) 1994-01-13 1994-01-13 Method of treating hyperproliferative vascular disease

Publications (1)

Publication Number Publication Date
DK0665013T3 true DK0665013T3 (da) 2002-02-18

Family

ID=22662966

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95100194T DK0665013T3 (da) 1994-01-13 1995-01-09 Behandling af hyperproliferative karsygdomme

Country Status (10)

Country Link
US (1) US5519042A (de)
EP (1) EP0665013B1 (de)
JP (1) JP2843774B2 (de)
AT (1) ATE207355T1 (de)
AU (1) AU696851B2 (de)
CA (1) CA2140106C (de)
DE (1) DE69523350T2 (de)
DK (1) DK0665013T3 (de)
ES (1) ES2166381T3 (de)
PT (1) PT665013E (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
DE69937904T2 (de) * 1998-03-11 2009-01-02 James W. Oak Park Williams Antivirale verwendungen von leflunomid produkten
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
AU2002249958B2 (en) * 2001-01-16 2007-11-08 Vascular Therapies, Inc. Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
CN100469394C (zh) * 2001-02-16 2009-03-18 艾伯特实验室血管有限公司 具有fk506的植入体
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
PL372902A1 (en) * 2002-04-16 2005-08-08 Astellas Pharma Inc. New use
US7309349B2 (en) * 2003-01-23 2007-12-18 Cordis Corporation Friction reducing lubricant for stent loading and stent delivery systems
US6894184B2 (en) * 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
DE10311763A1 (de) * 2003-03-18 2004-10-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 2-Cyan-3-hydroxy-N-(phenyl)but-2-enamiden
EP2012861A4 (de) * 2006-04-17 2010-03-10 Hadasit Med Res Service Ptca-führungskatheter mit extralumen zur kontinuierlichen infusion von medikamenten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
AU7854291A (en) * 1990-04-27 1991-11-27 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
DE59203828D1 (de) * 1991-10-23 1995-11-02 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft.
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers

Also Published As

Publication number Publication date
AU696851B2 (en) 1998-09-17
DE69523350D1 (de) 2001-11-29
ATE207355T1 (de) 2001-11-15
US5519042A (en) 1996-05-21
CA2140106C (en) 2006-12-12
ES2166381T3 (es) 2002-04-16
DE69523350T2 (de) 2002-07-04
PT665013E (pt) 2002-03-28
EP0665013B1 (de) 2001-10-24
JPH07277976A (ja) 1995-10-24
JP2843774B2 (ja) 1999-01-06
AU1015095A (en) 1995-07-20
EP0665013A1 (de) 1995-08-02
CA2140106A1 (en) 1995-07-14

Similar Documents

Publication Publication Date Title
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
DE3751006D1 (de) Psychostimulierendes mittel.
DE69623899D1 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
PT80820B (pt) Processo para a preparacao de derivados de 1,3-propilidenodifosfonato 2-substituidos
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser
FI895229A7 (fi) Yhdisteitä virtsan pidätyskyvyttömyyden hoitoon
DE69825980D1 (de) 4,5-dihydroxy-2-cyclopentene-1-on für die behandlung von rheumatismus, entzündungen und autoimmunerkrankungen
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
FI925546A7 (fi) Amidiliittyneitä pyridyylihappojohdannaisia leukotrieeniin liittyvien sairauksien hoitamiseksi
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
BR9710901A (pt) M-todo para o tratamento da doen-a bipolar
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE146964T1 (de) Behandlung von katarakt mit prostacyclinverbindungen
FI945035A0 (fi) Pintasterilisointi laserkäsittelyn avulla
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
DE69116187D1 (de) Verwendung eines Dihydropyridins zur Verbesserung der Blutzirkulation des inneren Ohres